[1] |
Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med, 2016, 375(18): 1767-1778. doi:10.1056/NEJMra1514296.
doi: 10.1056/NEJMra1514296.
URL
|
[2] |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 2011, 331(6024): 1565-1570. doi:10.1126/science.1203486.
doi: 10.1126/science.1203486
pmid: 21436444
|
[3] |
Lee JJ, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphoma. Acta Oncol, 2016, 55(4): 519-520. doi:10.3109/0284186X.2015.1125017.
doi: 10.3109/0284186X.2015.1125017.
URL
|
[4] |
Fujita K, Terashima T, Mio T. Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. J Thorac Oncol, 2016, 11(12): 2238-2240. doi:10.1016/j.jtho.2016.07.006.
doi: S1556-0864(16)30605-0
pmid: 27423391
|
[5] |
Chu YC, Fang KC, Chen HC, et al. Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti-PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma. J Thorac Oncol, 2017, 12(8): e111-e114. doi:10.1016/j.jtho.2017.03.012.
doi: 10.1016/j.jtho.2017.03.012.
|
[6] |
Takata S, Koh G, Han Y, et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents. J Infect Chemother, 2019, 25(1): 54-58. doi:10.1016/j.jiac.2018.06.016.
doi: S1341-321X(18)30189-2
pmid: 30055859
|
[7] |
Anastasopoulou A, Ziogas DC, Samarkos M, et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer, 2019, 7(1): 239. doi:10.1186/s40425-019-0717-7.
doi: 10.1186/s40425-019-0717-7
pmid: 31484550
|
[8] |
Barber DL, Sakai S, Kudchadkar RR, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med, 2019, 11(475): eaat2702. doi:10.1126/scitranslmed.aat2702.
doi: 10.1126/scitranslmed.aat2702.
|
[9] |
Sirgiovanni M, Hinterleitner C, Horger M, et al. Long-term remission of small cell lung cancer after reactivation of tuberculosis following immune-checkpoint blockade: A case report. Thorac Cancer, 2021, 12(5): 699-702. doi:10.1111/1759-7714.13821.
doi: 10.1111/1759-7714.13821
pmid: 33458956
|
[10] |
Kato Y, Watanabe Y, Yamane Y, et al. Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report. Immunotherapy, 2020, 12(6): 373-378. doi:10.2217/imt-2020-0061.
doi: 10.2217/imt-2020-0061
pmid: 32314636
|
[11] |
Lau KS, Cheung BM, Lam KO, et al. Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. BMC Infect Dis, 2021, 21(1): 1148. doi:10.1186/s12879-021-06845-7.
doi: 10.1186/s12879-021-06845-7.
URL
|
[12] |
Suliman AM, Bek SA, Elkhatim MS, et al. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review. Cancer Immunol Immunother, 2021, 70(4): 935-944. doi:10.1007/s00262-020-02726-1.
doi: 10.1007/s00262-020-02726-1
pmid: 33070259
|
[13] |
Murakami S, Usui R, Nakahara Y, et al. Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy. Intern Med, 2021, 60(11): 1743-1746. doi:10.2169/internalmedicine.6002-20.
doi: 10.2169/internalmedicine.6002-20.
URL
|
[14] |
Riudavets M, Wyplosz B, Ghigna MR, et al. Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report. JTO Clin Res Rep, 2022, 3(5): 100319. doi:10.1016/j.jtocrr.2022.100319.
doi: 10.1016/j.jtocrr.2022.100319.
|
[15] |
Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers, 2020, 6(1): 38. doi:10.1038/s41572-020-0160-6.
doi: 10.1038/s41572-020-0160-6
pmid: 32382051
|
[16] |
Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J, 2019, 42(5): 299-306. doi:10.1016/j.bj.2019.09.002.
doi: 10.1016/j.bj.2019.09.002.
URL
|
[17] |
Lázár-Molnár E, Chen B, Sweeney KA, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A, 2010, 107(30): 13402-13407. doi:10.1073/pnas.1007394107.
doi: 10.1073/pnas.1007394107.
URL
|
[18] |
Ogishi M, Yang R, Aytekin C, et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med, 2021, 27(9): 1646-1654. doi:10.1038/s41591-021-01388-5.
doi: 10.1038/s41591-021-01388-5
pmid: 34183838
|
[19] |
Ou SL, Luo J, Wei H, et al. Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews. Front Immunol, 2022, 13: 953761. doi:10.3389/fimmu.2022.953761.
doi: 10.3389/fimmu.2022.953761.
URL
|
[20] |
Tezera LB, Bielecka MK, Ogongo P, et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. Elife, 2020, 9: e52668. doi:10.7554/eLife.52668.
doi: 10.7554/eLife.52668.
|
[21] |
Day CL, Abrahams DA, Bunjun R, et al. PD-1 Expression on Mycobacterium tuberculosis-Specific CD 4 T Cells Is Associated With Bacterial Load in Human Tuberculosis. Front Immunol, 2018, 9: 1995. doi:10.3389/fimmu.2018.01995.
doi: 10.3389/fimmu.2018.01995.
URL
|
[22] |
Fishman JA, Hogan JI, Maus MV. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Clin Infect Dis, 2019, 69(6):909-920. doi:10.1093/cid/ciy1025.
doi: 10.1093/cid/ciy1025
pmid: 30520987
|